Table 2.
List of all drug synergisms
| Drugs | Side eff. | Syn. | ratio | Class |
|---|---|---|---|---|
|
Rosiglitazone (#7) - Quinacrine (#36) - Cerulenin (#62) - Tyloxapol (#85) |
363.8 |
91 |
25.0% |
A |
| Rosiglitazone (#7) - Quinacrine (#36) - Orlistat (#65) - Tyloxapol (#85) |
377.7 |
91 |
24.0% |
A |
|
Rosiglitazone (#7) - Indomethacin (#22) - Cerulenin (#62) - Tyloxapol (#85) |
390.6 |
91 |
23.2% |
A |
|
Rosiglitazone (#7) - Diclofenac (#35) - Cerulenin (#62) - Tyloxapol (#85) |
397.5 |
91 |
22.8% |
A |
| Rosiglitazone (#7) - Indomethacin (#22) - Orlistat (#65) - Tyloxapol (#85) |
404.5 |
91 |
22.4% |
A |
| Rosiglitazone (#7) - Diclofenac (#35) - Orlistat (#65) - Tyloxapol (#85) |
411.4 |
91 |
22.1% |
A |
|
Rosiglitazone (#7) - Cerulenin (#62) |
298.9 |
52 |
17.3% |
A |
| Rosiglitazone (#7) - Orlistat (#65) - |
312.8 |
52 |
16.6% |
A |
| Indomethacin (#22) - Fomepizole (#75) |
84.7 |
1 |
1.1% |
B |
| Naftifine (#43) - Acetylsalicylic acid (#55) |
116.0 |
6 |
5.1% |
C |
| Acetylsalicylic acid (#55) - Tioconazole (#60) |
116.0 |
6 |
5.1% |
C |
|
Simvastatin/Pravastatin (#4) - Acetylsalicylic acid (#55) |
123.9 |
6 |
4.8% |
C |
| Rosiglitazone (#7) - Tioconazole (#60) |
280.9 |
6 |
2.1% |
C |
| Rosiglitazone (#7) - Naftifine (#43) |
280.9 |
6 |
2.1% |
C |
|
Simvastatin/Pravastatin (#4) - Rosiglitazone (#7) |
288.8 |
6 |
2.0% |
C |
| Carbidopa (#6) - Droxidopa (#24) |
93.1 |
1 |
1.0% |
D |
| Droxidopa (#24) - Selegiline (#45) |
96.1 |
1 |
1.0% |
D |
| Droxidopa (#24) - Minaprine (#49) |
152.4 |
1 |
0.6% |
D |
| Droxidopa (#24) - Zonisamide (#54) |
289.7 |
1 |
0.3% |
D |
| Mycophenolic acid (#42) - Mercaptopurine (#58) |
11.0 |
5 |
45.4% |
E |
| Ribavirin (#51) - Mercaptopurine (#58) |
23.9 |
5 |
20.9% |
E |
| Udenafil (#10) - Mycophenolic acid (#42) - Mercaptopurine (#58) - |
18.0 |
7 |
38.8% |
E |
| Mycophenolic acid (#42) - Dipyridamole (#57) - Mercaptopurine (#58) |
22.0 |
7 |
31.8% |
E |
| Udenafil (#10) - Ribavirin (#51) - Mercaptopurine (#58) |
30.9 |
7 |
22.6% |
E |
| Ribavirin (#51) - Dipyridamole (#57) - Mercaptopurine (#58) |
34.9 |
7 |
20,0% |
E |
| Theophylline (#18) - Mycophenolic acid (#42) - Mercaptopurine (#58) |
41.7 |
7 |
16.7% |
E |
| Mycophenolic acid (#42) - Pentoxifylline (#50) - Mercaptopurine (#58) |
53.8 |
7 |
13.0% |
E |
| Theophylline (#18) - Ribavirin (#51) - Mercaptopurine (#58) |
54.6 |
6 |
10.9% |
E |
| Pentoxifylline (#50) - Ribavirin (#51) - Mercaptopurine (#58) |
66.7 |
6 |
8.9% |
E |
| Pentoxifylline (#50) - Arsenic trioxide (#72) |
118.2 |
17 |
14.3% |
F |
| Cladribirne (#16) - Pentoxifylline (#50) |
118.2 |
17 |
14.3% |
F |
| Gemcitabine (#30) - Pentoxifylline (#50) | 157.8 | 15 | 9.5% | F |
The table reports the multiple drug solutions in the human metabolic network, the side effect σ(D), the synergism size (i.e. the number of stopped reactions which exceeds the linear superposition of single drug effects), the ratio between these two quantities, and their classification (see Figure 2 and main text for the clustering analysis). Drug numbers refer to Additional file 1: Table S1. Bold font indicates that the solution (or part of it) has an experimental validation.